Status:
COMPLETED
Tedizolid Neuropathies
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Adult Patients Developing Optic or Peripheral Neuropathy
While Receiving Tedizolid Therapy Between July 2019 and December 2024
Eligibility:
All Genders
Brief Summary
Tedizolid is a new oxazolidinone, related to linezolid. It has obtained marketing authorization for the treatment of skin and soft tissue infections. Its potential interest compared to linezolid lies ...
Eligibility Criteria
Inclusion
- 18 years
- Patients developing optic or peripheral neuropathy while receiving tedizolid therapy
Exclusion
- 18 years
Key Trial Info
Start Date :
March 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT07143240
Start Date
March 1 2025
End Date
May 1 2025
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HCL
Lyon, France, France, 69004